Ketanserin: A novel cardiovascular drug | Zendy

Symoens Jan | Zendy; Janssens Monique | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Ketanserin: A novel cardiovascular drug

Author(s) -

Symoens Jan,

Janssens Monique

Publication year - 1986

Publication title -

drug development research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.582

H-Index - 60

eISSN - 1098-2299

pISSN - 0272-4391

DOI - 10.1002/ddr.430080119

Subject(s) - ketanserin , medicine , drug , hemodynamics , microcirculation , pharmacology , serotonin , cardiology , 5 ht receptor , receptor

Extensive clinical investigation has shown that ketanserin is an effective first‐line antihypertensive agent with particular advantages in older patients. It has a favorable hemodynamic profile and seems devoid of serious side‐effects. Clinical studies in various diseases indicate a gradual improvement of the microcirculation, which is compatible with selective serotonin S 2 ‐antagonism. Ketanserin has a favorable influence on several cardiovascular risk factors. Preliminary data suggest that it has vascular protective effects in patients with atherosclerosis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research